Published in AIDS Weekly, April 26th, 2004
"Aminoglycoside-arginine conjugates (AACs) inhibit HIV-1 replication and act as Tat antagonists," scientists in Israel explained. "AACs compete with monoclonal antibody binding to CXCR4" and with "SDF-1alpha and HIV-1 gp120 cellular uptake, indicating that they interfere with initial steps of HIV-1 infection."
G. Borkow and colleagues working at the Weizmann Institute of Science in Rehovot described "the selection of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate (NeoR6), the most potent anti-HIV-1 AAC."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.